STALEY CAPITAL ADVISERS’s State Street SPDR S&P Biotech ETF XBI Stock Holding History

STALEY CAPITAL ADVISERS’s Portfolio XBI Stock Details XBI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$3.04M	Buy	19,220 +1,155	+6%	+$156K	0.12%	69
2026 Q1	$2.31M	Buy	18,065 +3,700	+26%	+$462K	0.1%	76
2025 Q4	$1.75M	Sell	14,365 -20	-0.1%	-$2.29K	0.07%	91
2025 Q3	$1.44M	Hold	14,385	–	–	0.06%	93
2025 Q2	$1.19M	Sell	14,385 -1,700	-11%	-$136K	0.05%	105
2025 Q1	$1.3M	Sell	16,085 -1,930	-11%	-$173K	0.06%	98
2024 Q4	$1.62M	Buy	18,015 +50	+0.3%	+$4.84K	0.07%	89
2024 Q3	$1.77M	Sell	17,965 -550	-3%	-$54K	0.08%	82
2024 Q2	$1.72M	Buy	18,515 +300	+2%	+$26.9K	0.08%	83
2024 Q1	$1.73M	Sell	18,215 -100	-0.5%	-$9.28K	0.08%	79
2023 Q4	$1.64M	Sell	18,315 -28,770	-61%	-$2.14M	0.08%	83
2023 Q3	$3.44M	Buy	47,085 +250	+0.5%	+$20K	0.19%	60
2023 Q2	$3.9M	Sell	46,835 -1,185	-2%	-$99.1K	0.21%	58
2023 Q1	$3.66M	Sell	48,020 -610	-1%	-$50.6K	0.2%	58
2022 Q4	$4.04M	Sell	48,630 -19,152	-28%	-$1.55M	0.24%	56
2022 Q3	$5.38M	Buy	67,782 +11,300	+20%	+$953K	0.34%	50
2022 Q2	$4.2M	Buy	56,482 +15,640	+38%	+$1.17M	0.25%	55
2022 Q1	$3.67M	Buy	+40,842	New	+$3.77M	0.19%	63

Other funds holding XBI

BNP Paribas Financial Markets Paris, France $289B AUM 60.46% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Citigroup New York $303B AUM 53.02% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Healthcare of Ontario Pension Plan (HOOPP) Trust Fund Toronto, Ontario, Canada $71.2B AUM 48.86% 1-Year Est. Return

Wells Fargo San Francisco, California $617B AUM 30.33% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Barclays London, United Kingdom $521B AUM 51.41% 1-Year Est. Return

JFG

Jefferies Financial Group New York $15.2B AUM 55.75% 1-Year Est. Return

STALEY CAPITAL ADVISERS's XBI Position: Q2 2026 in Review

STALEY CAPITAL ADVISERS increased its State Street SPDR S&P Biotech ETF (XBI) stake by 6.4% in Q2 2026, buying an estimated $156K and bringing the position to 19,220 shares worth $3.04M. The position accounts for 0.12% of the portfolio, ranked #69.

STALEY CAPITAL ADVISERS first reported a position in XBI in Q1 2022 and has held it in 18 quarters since. The position peaked at $5.38M in Q3 2022. 933 funds tracked by Wall St. Rank hold XBI as of Q2 2026.

STALEY CAPITAL ADVISERS held 19,220 shares of State Street SPDR S&P Biotech ETF worth $3.04M as of Q2 2026.
STALEY CAPITAL ADVISERS bought 1,155 State Street SPDR S&P Biotech ETF shares in Q2 2026, an estimated $156K.
State Street SPDR S&P Biotech ETF made up 0.12% of STALEY CAPITAL ADVISERS's portfolio in Q2 2026, its #69 holding.
STALEY CAPITAL ADVISERS first reported a position in State Street SPDR S&P Biotech ETF in Q1 2022 and has held it in 18 quarters since.
STALEY CAPITAL ADVISERS's State Street SPDR S&P Biotech ETF position peaked at $5.38M in Q3 2022.
933 funds tracked by Wall St. Rank held State Street SPDR S&P Biotech ETF as of Q2 2026.

Based on STALEY CAPITAL ADVISERS's 13F filing for Q2 2026, filed 11 Aug 2026.